{"version":"1.0","provider_name":"Kompetenznetz Multiple Sklerose","provider_url":"https:\/\/kknms.woomera.de\/en\/","author_name":"Zo\u00eb Hunter","author_url":"https:\/\/kknms.woomera.de\/en\/author\/kknms-hunter\/","title":"Natalizumab-Biosimilar Tyruko\u00ae in Deutschland verf\u00fcgbar - Kompetenznetz Multiple Sklerose","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"47tAfESIHA\"><a href=\"https:\/\/kknms.woomera.de\/en\/natalizumab-biosimilar-tyruko-in-deutschland-verfuegbar\/\">Natalizumab-Biosimilar Tyruko\u00ae in Deutschland verf\u00fcgbar<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/kknms.woomera.de\/en\/natalizumab-biosimilar-tyruko-in-deutschland-verfuegbar\/embed\/#?secret=47tAfESIHA\" width=\"600\" height=\"338\" title=\"&#8220;Natalizumab-Biosimilar Tyruko\u00ae in Deutschland verf\u00fcgbar&#8221; &#8212; Kompetenznetz Multiple Sklerose\" data-secret=\"47tAfESIHA\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/kknms.woomera.de\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/kknms.woomera.de\/wp-content\/uploads\/2024\/02\/HG_POOL_news_proben.jpg","thumbnail_width":2327,"thumbnail_height":1049,"description":"15.02.2024 \u2013 Das Natalizumab-Biosimilar Tyruko\u00ae der Firma Sandoz ist seit dem 01. Februar 2024 in Deutschland zur Therapie der hochaktiven, schubf\u00f6rmig remittierend verlaufenden Multiplen Sklerose (RRMS) verf\u00fcgbar. Es ist das erste zugelassene Biosimilar f\u00fcr die MS-Therapie und wurde im Herbst 2023 von der European Medicines Agency (EMA) autorisiert. Der aktive Wirkstoff in Tyruko\u00ae ist Natalizumab, [&hellip;]"}